Arix Pegs LogicBio's Technology As 'Occam's Razor' Of Gene Therapy
Executive Summary
Gene therapy startup LogicBio, with input from Arix Biosciences, has raised almost $50m via a series B financing round; it plans to use the cash to continue development of a potential novel alternative to traditional gene therapy.
You may also be interested in...
IPO Update: Returns Sag As Seven More Biopharmas Go Public In September
The average return for the 54 drug developers that went public in the US during first three quarters of 2018 was 13.6% as of Oct. 1 versus 16.9% as of Aug. 31 for the 47 biopharma firms that launched IPOs during the first eight months of this year. September had seven new offerings after just two in August.
Arix To Nurture Next Generation Biotechs After UK IPO
The supply of "permanent" capital and the desire to be involved operationally in new life science companies are some of the aims of Arix Bioscience, a UK company aiming to float on the London Stock Exchange, possibly by the end of this month.
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.